序号 |
标题 |
次数 |
作者 |
发布时间 |
70291 |
p-SCN-Bn-DOTA,127985-74-4,可用于标记多肽 |
111 |
h |
2024-12-11 |
70292 |
PAMAM-PEG-DOTA-Gd,聚酰胺-胺聚乙二醇DOTA钆 |
83 |
h |
2024-12-11 |
70293 |
螯合剂多肽,cyclo(RGDFK(DOTA)) |
116 |
h |
2024-12-11 |
70294 |
质粒构建的原理及方法 |
452 |
axc |
2024-12-11 |
70295 |
什么是基因过表达(gene overexpression) |
861 |
axc |
2024-12-11 |
70296 |
m-PEG6-(CH2)6-phosphonic acid,cas:2028284-71-9 |
95 |
zcy |
2024-12-11 |
70297 |
1201415-84-0,1180007-00-4,DOTA-Lys-Cys-COOH |
76 |
h |
2024-12-11 |
70298 |
CRISPR/Cas9系统基因敲除个别外显子(操作步骤) |
394 |
axc |
2024-12-11 |
70299 |
大环螯合物DOTA,DOTA-RGD |
73 |
h |
2024-12-11 |
70300 |
BocNH-O-(CH₂)₅-COOH BOC 保护基-氨基-五碳链-羧酸 |
120 |
zcy |
2024-12-11 |
70301 |
基因敲除方法,基因敲除小鼠定制服务 |
159 |
axc |
2024-12-11 |
70302 |
"Maleimide-(CH2)5-COONHS cas:55750-63-5 6-(马来酰亚胺基)己酸琥珀酰亚胺酯" |
90 |
zcy |
2024-12-11 |
70303 |
质粒构建的原理、步骤|质粒构建定制服务 |
387 |
axc |
2024-12-11 |
70304 |
DOTA-「Tyr3」-Octreotide,Edotreotide,奥曲肽的多肽 |
125 |
h |
2024-12-11 |
70305 |
Mal-PEG-CH2CO2H(马来酰亚胺) |
91 |
WYQ |
2024-12-11 |
70306 |
Stearic acid-PEG-CH2CO2H |
121 |
WYQ |
2024-12-11 |
70307 |
Dotatate,DOTA-奥曲肽 |
119 |
h |
2024-12-11 |
70308 |
螯合剂多肽DOTA-cyclo(RGDfK) |
101 |
h |
2024-12-11 |
70309 |
Biotin-PEG-CH2CO2H(生物素)(聚乙二醇)(甲基羧酸) |
140 |
WYQ |
2024-12-11 |
70310 |
Pomalidomide-PEG4-CH2COOH (CAS: 2097938-44-6) |
84 |
WYQ |
2024-12-11 |
70311 |
Pomalidomide-PEG2-CH2COOH (CAS: 2143097-05-4) |
89 |
WYQ |
2024-12-11 |
70312 |
Hydroxy-PEG1-CH2-Boc |
101 |
kx |
2024-12-11 |
70313 |
Thalidomide-O-PEG2-CH2-Ald (CAS: 2286368-58-7) |
128 |
WYQ |
2024-12-11 |
70314 |
双功能螯合剂DOTA-多肽;DOTA-cRGD 大环螯合剂修饰靶向环肽 |
98 |
h |
2024-12-11 |
70315 |
DSPE-PEG-CH2COOH(CAS: 474922-20-8) |
129 |
WYQ |
2024-12-11 |
70316 |
质粒构建的过程,制备方法 |
266 |
axc |
2024-12-11 |
70317 |
Tos-PEG1-CH2-Boc的应用和用途 |
117 |
kx |
2024-12-11 |
70318 |
204318-14-9,DOTA-(Tyr3)-octreotate,依多曲肽 |
67 |
h |
2024-12-11 |
70319 |
"Maleimide-(CH2)2-COOH cas:7423-55-4 3-马来酰亚胺基丙酸" |
144 |
zcy |
2024-12-11 |
70320 |
Propargyl-PEG3-CH2CO2H |
130 |
WYQ |
2024-12-11 |
70321 |
DOTA多肽分子探针,619300-53-7 |
104 |
h |
2024-12-11 |
70322 |
t-Boc-Aminooxy-PEG2-CH2CO2tBu(CAS: 2100306-57-6) |
76 |
WYQ |
2024-12-11 |
70323 |
β-NF-CH2-OH |
122 |
kx |
2024-12-11 |
70324 |
PEG5-(CH2CO2t-Butyl)2(CAS: 211746-78-0) |
115 |
WYQ |
2024-12-11 |
70325 |
Hydroxy-PEG4-CH2-Boc |
148 |
kx |
2024-12-11 |
70326 |
PEG6-(CH2CO2t-Butyl)2(CAS: 211746-79-1) |
120 |
WYQ |
2024-12-11 |
70327 |
七肽DOTA-YLYEIAR,1262403-91-7 |
104 |
h |
2024-12-11 |
70328 |
质粒构建的原理与类型 |
125 |
axc |
2024-12-11 |
70329 |
Thalidomide-5-NH2-CH2-COOH |
112 |
kx |
2024-12-11 |
70330 |
Cbz-N-Amido-PEG4-CH2COOH(CAS: 1451362-51-8) |
133 |
WYQ |
2024-12-11 |
70331 |
HO-PEG10-CH2COOtBu |
82 |
|
2024-12-11 |
70332 |
t-butyl ester-PEG4-CH2COOH (CAS: 929087-83-2) |
132 |
WYQ |
2024-12-11 |
70333 |
什么是载体构建与质粒构建 |
166 |
axc |
2024-12-11 |
70334 |
Fmoc-Gly-NH-CH2-acetyloxy |
75 |
kx |
2024-12-11 |
70335 |
Fmoc-N-amido-PEG11-CH2-aldehyde |
124 |
WYQ |
2024-12-11 |